2Seventy Bio Inc TSVT.OQ TSVT.O is expected to show a rise in quarterly revenue when it reports results on March 17 (estimated) for the period ending December 31 2024
The Cambridge Massachusetts-based company is expected to report a 8.6% increase in revenue to $11.599 million from $10.68 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for 2Seventy Bio Inc is for a loss of 26 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for 2Seventy Bio Inc is $5.00, above its last closing price of $4.95.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.23 | -0.24 | -0.19 | Beat | 21.2 |
Jun. 30 2024 | -0.76 | -0.65 | 0.45 | Beat | 169.5 |
Mar. 31 2024 | -0.79 | -0.81 | -1.01 | Missed | -24.4 |
Dec. 31 2023 | -1.05 | -0.99 | -1.11 | Missed | -12.1 |
Sep. 30 2023 | -1.20 | -1.03 | -1.00 | Beat | 2.8 |
Jun. 30 2023 | -1.09 | -1.06 | -0.83 | Beat | 22.1 |
Mar. 31 2023 | -1.20 | -1.19 | -1.08 | Beat | 9.5 |
Dec. 31 2022 | -1.59 | -1.61 | -0.60 | Beat | 62.6 |
This summary was machine generated March 14 at 12:36 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。